Literature DB >> 22337690

Oestrogen-related tumour phenotype: positron emission tomography characterisation with ¹⁸F-FDG and ¹⁸F-FES.

T Tsujikawa1, Y Yoshida, H Maeda, T Tsuchida, T Mori, Y Kiyono, H Kimura, H Okazawa.   

Abstract

This article outlines the role of 16α-[(18)F]fluoro-17β-oestradiol ((18)F-FES) positron emission tomography (PET) combined with 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) in patients with oestrogen-related tumours for evaluating tumour phenotype. (18)F-FES-PET combined with (18)F-FDG is helpful in characterising the distinct phenotypic features of oestrogen-related tumours; that is, inter- and intrapatient tumour heterogeneity, which indicates its great potential as a determinant of individualised treatment and a prognostic predictor for patients with oestrogen-related tumours.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22337690      PMCID： PMC3474065          DOI： 10.1259/bjr/26645378

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


  24 in total

1.  Imaging tumor phenotype: 1 plus 1 is more than 2.

Authors:  David A Mankoff; Farrokh Dehdashti
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

2.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Authors:  David Groheux; Sylvie Giacchetti; Jean-Luc Moretti; Raphael Porcher; Marc Espié; Jacqueline Lehmann-Che; Anne de Roquancourt; Anne-Sophie Hamy; Caroline Cuvier; Laetitia Vercellino; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-06       Impact factor: 9.236

3.  Additional value of 16α-[18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET.

Authors:  Yoshio Yoshida; Yasushi Kiyono; Tetsuya Tsujikawa; Tetsuji Kurokawa; Hidehiko Okazawa; Fumikazu Kotsuji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06-08       Impact factor: 9.236

4.  18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.

Authors:  Joseph R Osborne; Elisa Port; Mithat Gonen; Ashley Doane; Henry Yeung; William Gerald; Josh B Cook; Steven Larson
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

5.  Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.

Authors:  J E Mortimer; F Dehdashti; B A Siegel; K Trinkaus; J A Katzenellenbogen; M J Welch
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

6.  Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.

Authors:  Tetsuya Tsujikawa; Yoshio Yoshida; Yasushi Kiyono; Tetsuji Kurokawa; Takashi Kudo; Yasuhisa Fujibayashi; Fumikazu Kotsuji; Hidehiko Okazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-18       Impact factor: 9.236

7.  The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer.

Authors:  Keiichiro Nakamura; Junichi Kodama; Yoshihiro Okumura; Atsushi Hongo; Susumu Kanazawa; Yuji Hiramatsu
Journal:  Int J Gynecol Cancer       Date:  2010-01       Impact factor: 3.437

8.  Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.

Authors:  Tetsuya Tsujikawa; Yoshio Yoshida; Takashi Kudo; Yasushi Kiyono; Tetsuji Kurokawa; Masato Kobayashi; Tatsuro Tsuchida; Yasuhisa Fujibayashi; Fumikazu Kotsuji; Hidehiko Okazawa
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

9.  Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma.

Authors:  A H McGuire; F Dehdashti; B A Siegel; A P Lyss; J W Brodack; C J Mathias; M A Mintun; J A Katzenellenbogen; M J Welch
Journal:  J Nucl Med       Date:  1991-08       Impact factor: 10.057

10.  Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.

Authors:  F Dehdashti; J E Mortimer; B A Siegel; L K Griffeth; T J Bonasera; M J Fusselman; D D Detert; P D Cutler; J A Katzenellenbogen; M J Welch
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.